Galena's shares jump on ASCO data; BMS has created a cancer vaccine network;

> Galena's ($GALE) shares have jumped by 14% on five-year NeuVax data presented at ASCO. Press release | Press release | Article

> Bristol-Myers Squibb ($BMY) has created the International Immuno-Oncology Network (II-ON), a network of 10 institutions, to develop cancer vaccines. Article

> Jennerex is presenting Phase II JX-594 clinical data at ASCO 2012. Press release

> Ventria Bioscience division InVitria has been awarded a $1.5 million SBIR grant from the NIH to develop an animal-free cell culture media for the commercial production of cell-based vaccines. Press release

> Researchers at Yeshiva University have received a 5-year, $5.9 million grant from the NIH to develop a tuberculosis vaccine. Article

> Generex has presented further data at ASCO from its ongoing Phase IIb cancer vaccine, AE37, which show more information about its mechanism of action. Abstract | Press release

> Harvard spinoff Vaxess Technologies has won the Harvard University President's Challenge for social entrepreneurship, receiving $70,000 to create a silk-based technology to store vaccines without refrigeration. Article

> A new technique to diagnose malaria could lead to new vaccines. Article

> SIV infection leads to potential new target for HIV vaccines. Press release

> Immunovaccine has presented Phase I data at ASCO for its DPX-0907 therapeutic cancer vaccine in patients with breast or ovarian cancer. Press release

> OPKO Health has acquired a stake in an Israeli hepatitis B vaccine manufacturer. Press release

> Around 76% of healthcare providers do not store vaccines at the right temperature, according to the CDC. Article

> Taiwan and Canada are collaborating to develop infectious disease vaccines, with clinical trials expected within 5 years. Article

And Finally… Surplus electricity from cellphone towers could run fridges to keep vaccines cool in developing countries. Article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.